Meta tags:
keywords=;
description=;

Headings (most frequently used words):

you, about, to, exit, abbott, website, investors, newsroom, responsibility, careers, press, releases, are, for, another, country, or, region, specific, do, wish, continue, and, this, subscribe, consumers, healthcare, professionals, partners, contact, site, map, policies, privacy, policy, terms, conditions,

Text of the page (most frequently used words):
the (64), and (53), #abbott (42), exact (18), sciences (18), transaction (17), cancer (14), proposed (13), for (12), that (11), with (11), 2026 (9), people (9), our (9), diagnostics (9), other (8), are (8), loading (7), this (7), all (7), statements (7), more (7), not (6), about (6), risks (6), forward (6), looking (6), healthcare (6), screening (6), overview (6), you (5), website (5), site (5), may (5), any (5), ability (5), business (5), acquisition (5), professionals (5), its (4), privacy (4), financial (4), from (4), events (4), regulatory (4), benefits (4), leading (4), growth (4), share (4), growing (4), march (4), press (4), responsibility (4), careers (4), faqs (4), medical (3), products (3), also (3), otherwise (3), product (3), policy (3), conditions (3), uncertainties (3), sec (3), operations (3), related (3), such (3), possible (3), parties (3), expected (3), will (3), announcement (3), life (3), approximately (3), detect (3), treatment (3), decisions (3), help (3), test (3), leadership (3), fast (3), segments (3), close (3), content (3), releases (3), contact (3), consumers (3), subscribe (3), exit (2), please (2), have (2), requested (2), country (2), region (2), result (2), information (2), devices (2), those (2), countries (2), specific (2), trade (2), made (2), except (2), identify (2), company (2), further (2), preferences (2), health (2), terms (2), policies (2), 224 (2), 668 (2), factors (2), businesses (2), risk (2), annual (2), report (2), form (2), year (2), ended (2), their (2), does (2), december (2), 2025 (2), personnel (2), including (2), management (2), others (2), results (2), litigation (2), among (2), could (2), include (2), inability (2), timely (2), basis (2), give (2), rise (2), expectations (2), possibility (2), complete (2), than (2), anticipated (2), synergies (2), realized (2), market (2), stock (2), leader (2), stages (2), portfolio (2), changing (2), technologies (2), facebook (2), linkedin (2), sales (2), accelerate (2), billion (2), advancing (2), pipeline (2), earlier (2), manage (2), disease (2), offerings (2), personalized (2), early (2), recurrence (2), guide (2), care (2), strengthens (2), new (2), precision (2), oncology (2), strategic (2), executive (2), enables (2), enter (2), lead (2), serving (2), millions (2), additional (2), follows (2), receipt (2), clearances (2), necessary (2), closing (2), file (2), set (2), newsroom (2), investors (2), glance (2), heritage (2), who (2), search (2), jobs (2), conferences (2), culture (2), students (2), working (2), news (2), yes, wish, continue, aware, intended, residents, particular, noted, contain, pharmaceuticals, uses, approved, regions, optimized, your, screen, size, another, unless, specified, service, names, appearing, internet, trademarks, owned, licensed, subsidiaries, affiliates, use, trademark, name, dress, without, prior, written, authorization, services, rights, reserved, read, legal, notice, details, submit, eventtype, pageurl, advertising, myabbott, consumer, data, media, scott, stoffel, 5201, michael, comilla, 1872, source, should, carefully, consider, foregoing, affect, described, section, each, respectively, respective, reports, filed, free, copies, these, documents, obtained, speak, only, date, they, readers, cautioned, put, undue, reliance, undertakes, obligation, intend, release, publicly, revisions, subsequent, developments, required, law, www, gov, develop, maintain, relationships, attract, retain, highly, qualified, scientific, customers, suppliers, whom, condition, performance, diversion, attention, ongoing, due, actions, outcome, action, communication, contains, things, involve, substantial, cause, actual, differ, materially, expressed, implied, following, consummate, satisfy, precedent, consummation, occurrence, event, change, circumstance, termination, definitive, agreement, successfully, integrate, implement, plans, forecasts, respect, after, completion, relating, significant, costs, associated, expensive, realize, within, time, period, potential, adverse, effects, pendency, failure, price, common, global, helps, live, fully, spans, spectrum, nutritionals, branded, generic, medicines, 115, 000, colleagues, serve, 160, connect, youtube, instagram, com, previously, communicated, add, incremental, dilute, adjusted, earnings, per, eps, next, generation, designed, even, optimize, enable, regular, monitoring, stay, healthy, better, cologuard, noninvasive, colorectal, option, oncotype, which, informs, patients, stage, breast, oncodetect, tumor, informed, molecular, residual, mrd, follow, cancerguard, multi, detection, blood, industry, position, capabilities, positioning, advance, preventative, predictive, expands, presence, one, fastest, areas, incidence, continues, worldwide, adds, vertical, already, high, single, digit, establishing, genetic, testing, helping, monitor, fit, proactively, shaping, anticipate, future, needs, while, building, long, term, shareholder, value, remains, core, framework, said, chairman, chief, officer, addition, enhances, profile, brings, powerful, platform, into, mission, make, accessible, control, over, robert, ford, together, innovation, expand, access, earliest, most, treatable, nyse, abt, today, announced, expects, monday, prnewswire, ill, park, download, view, twitter, back, map, partners, fund, sustainability, social, impact, team, experts, honors, contacts, governance, resources, info, financials, mar,

Text of the page (random words):
abbott acquisition of exact sciences set to close on march 23 2026 mar 20 2026 investors overview financials stock info resources news events governance newsroom news press releases press contacts honors experts executive team responsibility overview social impact sustainability abbott fund subscribe consumers consumers healthcare professionals healthcare professionals careers overview working with us professionals students our people and culture benefits faqs conferences events search jobs careers overview working with us professionals students our people and culture benefits faqs conferences events search jobs about abbott overview who we are our heritage abbott at a glance abbott faqs contact us responsibility subscribe about abbott overview who we are our heritage abbott at a glance abbott faqs contact us responsibility subscribe consumers healthcare professionals careers about abbott careers investors newsroom responsibility partners contact site map policies privacy policy terms conditions press releases back to press releases abbott acquisition of exact sciences set to close on march 23 2026 share content to facebook share content to linkedin share content to twitter view file download file announcement follows receipt of all regulatory clearances necessary for closing transaction enables abbott to enter and lead in fast growing cancer screening and diagnostics segments serving millions of additional people abbott park ill march 20 2026 prnewswire abbott nyse abt today announced that it expects to close the acquisition of exact sciences on monday march 23 2026 the announcement follows receipt of all regulatory clearances necessary for closing the transaction enables abbott to enter and lead in fast growing cancer screening and diagnostics segments serving millions of additional people together with exact sciences abbott will accelerate innovation expand access to life changing diagnostics and help more people detect and manage cancer at its earliest most treatable stages proactively shaping the portfolio to anticipate future medical needs while building long term shareholder value remains at the core of our strategic framework said robert b ford chairman and chief executive officer abbott the addition of exact sciences enhances abbott s growth profile and strengthens our leadership in diagnostics this transaction brings a powerful new platform in cancer screening and diagnostics into abbott advancing our mission to make care more accessible and give people more control over their health strategic fit exact sciences is a leader in cancer screening precision oncology and genetic testing helping to detect cancer earlier guide treatment decisions and monitor for recurrence this acquisition strengthens abbott s leadership position and capabilities in diagnostics positioning the company to advance technologies that are more preventative predictive and personalized it expands abbott s presence in one of the fastest growing areas of healthcare as cancer incidence continues to rise worldwide it also adds a new growth vertical to abbott s already high single digit growth expectations establishing leadership in the fast growing 60 billion u s cancer screening and precision oncology diagnostics segments industry leading offerings and pipeline exact sciences product offerings include the cologuard test a market leading noninvasive colorectal cancer screening option oncotype dx which informs personalized treatment decisions for patients with early stage breast cancer oncodetect a tumor informed molecular residual disease mrd test to help identify cancer recurrence and guide follow up care and cancerguard a multi cancer early detection blood test exact sciences is also advancing a leading pipeline of next generation cancer diagnostics designed to detect cancer even earlier optimize treatment decisions and enable regular monitoring to help people stay healthy and better manage disease financial as previously communicated this transaction is expected to add approximately 3 billion of incremental sales in 2026 accelerate abbott s 2026 sales growth by approximately 0 5 and dilute 2026 adjusted earnings per share eps by approximately 0 20 about abbott abbott is a global healthcare leader that helps people live more fully at all stages of life our portfolio of life changing technologies spans the spectrum of healthcare with leading businesses and products in diagnostics medical devices nutritionals and branded generic medicines our 115 000 colleagues serve people in more than 160 countries connect with us at abbott com and on linkedin facebook instagram x and youtube forward looking statements this communication contains forward looking statements about among other things the proposed acquisition of exact sciences by abbott forward looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements such risks and uncertainties include among others the following the possible inability of the parties to consummate the proposed transaction on a timely basis or at all the possible inability of the parties to satisfy the conditions precedent to consummation of the proposed transaction on a timely basis or at all the possible occurrence of any event change or other circumstance that could give rise to the termination of the parties definitive agreement for the proposed transaction the ability of abbott to successfully integrate exact sciences operations and the ability of abbott to implement its plans forecasts and other expectations with respect to exact sciences business after the completion of the proposed transaction risks relating to significant transaction costs associated with the proposed transaction and the possibility that the proposed transaction may be more expensive to complete than anticipated risks related to the ability of abbott to realize the anticipated synergies and benefits of the proposed transaction including the possibility that the expected synergies and benefits from the proposed transaction will not be realized or will not be realized within the expected time period potential adverse effects of the announcement or pendency of the proposed transaction or any failure to complete the proposed transaction on the market price of abbott s common stock on the ability of exact sciences to develop and maintain relationships with its personnel including exact sciences ability to attract and retain highly qualified management and other scientific personnel and customers suppliers and others with whom it does business or otherwise on exact sciences or abbott s business financial condition results of operations and financial performance risks related to diversion of management s attention from exact sciences ongoing business operations due to the proposed transaction and the risk of litigation and or regulatory actions related to the proposed transaction or exact sciences business and the outcome of any such litigation or regulatory action you should carefully consider the foregoing factors and the other risks and uncertainties that affect the businesses of abbott and exact sciences described in the risk factors section in each of abbott s annual report on form 10 k for the year ended december 31 2025 and exact sciences annual report on form 10 k for the year ended december 31 2025 respectively and their respective other reports filed with the sec free copies of these documents may be obtained from the sec s website at www sec gov forward looking statements speak only as of the date they are made readers are cautioned not to put undue reliance on forward looking statements and abbott undertakes no obligation and does not intend to release publicly any revisions to forward looking statements as a result of subsequent events or developments or otherwise except as required by law source abbott for further information abbott media scott stoffel 224 668 5201 abbott financial michael comilla 224 668 1872 policies terms conditions privacy policy consumer health data privacy policy myabbott privacy preferences advertising preferences pageurl eventtype submit 2026 abbott all rights reserved please read the legal notice for further details unless otherwise specified all product and service names appearing in this internet site are trademarks owned by or licensed to abbott its subsidiaries or affiliates no use of any abbott trademark trade name or trade dress in this site may be made without the prior written authorization of abbott except to identify the product or services of the company you are about to exit for another abbott country or region specific website please be aware that the website you have requested is intended for the residents of a particular country or region as noted on that site as a result the site may contain information on pharmaceuticals medical devices and other products or uses of those products that are not approved in other countries or regions the website you have requested also may not be optimized for your specific screen size do you wish to continue and exit this website yes no loading loading loading loading loading loading loading